Relative bioavailability of etofibrate. A comparison of an acute and a new sustained release formulation.
The relative bioavailability of 2-(p-chlorophenoxy)-2-methylpropionic acid [2-(nicotinyloxy)-ethyl]-ester (etofibrate) from Lipo-Merz retard (500 mg) with respect to Lipo-Merz (600 mg) has been determined in 10 health volunteers in a crossover study. Etofibrate was determined in plasma after hydrolysis to clofibrinic acid. Pharmacokinetic parameters were derived to describe the plasma concentration-time profiles using a minimisation of least squares technique. The absorption was apparently delayed following the sustained release formulation with a longer time to maximum plasma concentration, which was significantly lower following the retard form. No significant differences were found in the mean apparent elimination half-lives nor areas under the plasma concentration-time curves indicating that the two formulations can be considered bioequivalent.
D000328:Adult; D001682:Biological Availability; D002994:Clofibrate / Q000031:analogs & derivatives* / Q000097:blood; D002995:Clofibric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D003692:Delayed-Action Preparations; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000378:metabolism*; D007700:Kinetics; D008297:Male
D003692:Delayed-Action Preparations; D000960:Hypolipidemic Agents; C009746:etofibrate; D002995:Clofibric Acid; D002994:Clofibrate